##################################################################################
# Document Properties
##################################################################################
SET DOCUMENT Name = "Gordon_et.al_2020.bel"
SET DOCUMENT Authors = "Abish K"
SET DOCUMENT ContactInfo = "abish@causalitybiomodels.com"
SET DOCUMENT Description = "COVID Knowledge Curation project"

SET DOCUMENT Licenses = "Private Ownership to Fraunhofer Institute SCAI"
SET DOCUMENT Copyright = "Copyright Â© 2020 Fraunhofer Institute SCAI, All rights reserved"
SET DOCUMENT Version = "2.0.0"

##################################################################################
# NAMESPACES Section
##################################################################################

DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"

# DEFINE NAMESPACE ADO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/alzheimer-disease-ontology/alzheimer-disease-ontology-1.0.2.belns"
# DEFINE NAMESPACE BRCO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/brain-region-ontology/brain-region-ontology-1.0.0.belns"
# DEFINE NAMESPACE NIFT AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/nift/NIFT.belns"

DEFINE NAMESPACE HGNC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20190708.belns"
# DEFINE NAMESPACE MGI AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-mouse-genes-20190128.belns"
# DEFINE NAMESPACE RGD AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-rat-genes-20190128.belns"
DEFINE NAMESPACE GFAM AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc-gene-families/hgnc-genefamily-names-20181221.belns"
# DEFINE NAMESPACE SCOMP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20190128.belns"
# DEFINE NAMESPACE SFAM AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20190128.belns"
# DEFINE NAMESPACE HP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20190130.belns"
DEFINE NAMESPACE CHEBI AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20190708.belns"
DEFINE NAMESPACE TAX AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-taxonomy/ncbi-taxonomy-20200322.belns"
DEFINE NAMESPACE DRUGBANK AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/drugbank/drugbank-20180906.belns"
# DEFINE NAMESPACE INTERPRO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-names-20181021.belns"
DEFINE NAMESPACE PFAM AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/pfam/pfam-names-20181024.belns"
DEFINE NAMESPACE DO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns"
DEFINE NAMESPACE GO AS URL 	"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns"
DEFINE NAMESPACE GOBP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20190128.belns"
DEFINE NAMESPACE GOCC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-cellular-component/go-cellular-component-20190128.belns"

DEFINE NAMESPACE MESH AS URL 	"https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh/mesh-names-20181007.belns"

# DEFINE NAMESPACE MESHC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-chemicals/mesh-chemicals-20190128.belns"
# DEFINE NAMESPACE MESHD AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-diseases/mesh-diseases-20190128.belns"
DEFINE NAMESPACE MESHPP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20190128.belns"

DEFINE NAMESPACE COVID AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/ncbi-covid19/ncbi-covid19-20200326.belns"
DEFINE NAMESPACE NCBIGENE AS PATTERN ".*"
DEFINE NAMESPACE REFSEQ AS PATTERN ".*"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM AS PATTERN "^\d+$"
# DEFINE NAMESPACE dbSNP AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE FIXME AS PATTERN ".*"

##################################################################################
# ANNOTATIONS Section
##################################################################################

# DEFINE ANNOTATION Anatomy AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20190128.belanno"
# DEFINE ANNOTATION CellLine AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20190128.belanno"
# DEFINE ANNOTATION Cell AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20190128.belanno"
# DEFINE ANNOTATION Disease AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20190128.belanno"
DEFINE ANNOTATION MeSHAnatomy AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20190128.belanno"
DEFINE ANNOTATION MeSHDisease AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20190128.belanno"
DEFINE ANNOTATION Species AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/species-taxonomy-id/species-taxonomy-id-20170511.belanno"
# DEFINE ANNOTATION TextLocation AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"
# DEFINE ANNOTATION BioAssay AS PATTERN ".*"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"

DEFINE ANNOTATION Experiment AS LIST {"GO enrichment analysis", "Literature derived", "Expert identified"}
DEFINE ANNOTATION Custom_Disease AS LIST {"COVID-19"}

# Document Annotations #
DEFINE ANNOTATION PublicationType AS LIST {"Research"}
DEFINE ANNOTATION PublicationStatus AS LIST {"Preprint"}
DEFINE ANNOTATION Section AS LIST {"Full Text"}

##################################################################################
# Statements #
##################################################################################
SET Citation = {"PubMed", "32353859"}
SET PublicationType = "Research"
SET Section = "Full Text"

SET Evidence = "Infection with these highly pathogenic coronaviruses can result in Acute Respiratory Distress Syndrome (ARDS), which may lead to long-term reduction in lung function, arrhythmia, and death."

SET Species = "9606"
SET Custom_Disease = "COVID-19"
a(TAX:"Severe acute respiratory syndrome coronavirus 2") -> path(DO:"COVID-19")
path(DO:"COVID-19") pos path(DO:"adult respiratory distress syndrome")
path(DO:"adult respiratory distress syndrome") pos path(DO:"lung disease")
path(DO:"adult respiratory distress syndrome") pos path(MESH:"Arrhythmias, Cardiac")
path(DO:"adult respiratory distress syndrome") pos path(MESH:Death)

SET Evidence = "For each of the viral proteins, we performed Gene Ontology enrichment analysis (Fig. 2b, Extended Data Fig. 2), identifying the major cell biological processes of the interacting proteins, including lipoprotein metabolism (S), nuclear transport (Nsp7), and biogenesis of ribonucleoprotein (Nsp8)."

p(COVID:S) reg bp(GO:"lipoprotein metabolic process")
p(COVID:ORF1ab, frag("3860_3942")) reg bp(GO:"nuclear transport")
p(COVID:ORF1ab, frag("3943_4140")) reg bp(GO:"ribonucleoprotein complex biogenesis")

SET Evidence = "Our study highlighted interactions between SARS-CoV-2 proteins and human proteins with a range of functions including DNA replication (Nsp1), epigenetic and gene expression regulators (Nsp5, Nsp8, Nsp13, E), vesicle trafficking (Nsp6, Nsp7, Nsp10, Nsp13, Nsp15, Orf3a, E, M, Orf8), lipid modification (Spike), RNA processing and regulation (Nsp8, N), ubiquitin ligases (Orf10), signaling (Nsp8, Nsp13, N, Orf9b), nuclear transport machinery (Nsp9, Nsp15, Orf6), cytoskeleton (Nsp1, Nsp13), mitochondria (Nsp4, Nsp8, Orf9c), and extracellular matrix (Nsp9) (Fig. 3)."

p(COVID:ORF1ab, frag("1_180")) reg bp(GO:"DNA replication")
p(COVID:ORF1ab, frag("3264_3569")) reg bp(GO:"regulation of gene expression, epigenetic")
p(COVID:ORF1ab, frag("3943_4140")) reg bp(GO:"regulation of gene expression, epigenetic")
p(COVID:ORF1ab, frag("5325_5925")) reg bp(GO:"regulation of gene expression, epigenetic")
p(COVID:E) reg bp(GO:"regulation of gene expression, epigenetic")
p(COVID:ORF1ab, frag("3570_3859")) reg bp(GO:"vesicle cytoskeletal trafficking")
p(COVID:ORF1ab, frag("3860_3942")) reg bp(GO:"vesicle cytoskeletal trafficking")
p(COVID:ORF1ab, frag("4254_4392")) reg bp(GO:"vesicle cytoskeletal trafficking")
p(COVID:ORF1ab, frag("5325_5925")) reg bp(GO:"vesicle cytoskeletal trafficking")
p(COVID:ORF1ab, frag("6453_6798")) reg bp(GO:"vesicle cytoskeletal trafficking")
p(COVID:ORF3a) reg bp(GO:"vesicle cytoskeletal trafficking")
p(COVID:E) reg bp(GO:"vesicle cytoskeletal trafficking")
p(COVID:M) reg bp(GO:"vesicle cytoskeletal trafficking")
p(COVID:ORF8) reg bp(GO:"vesicle cytoskeletal trafficking")
p(COVID:S) reg bp(GO:"lipid modification")
p(COVID:N) reg bp(GO:"RNA processing")
p(COVID:ORF1ab, frag("3943_4140")) reg bp(GO:"RNA processing")
p(COVID:ORF1ab, frag("4254_4392")) reg complex(GO:"ubiquitin ligase complex")
p(COVID:ORF1ab, frag("3943_4140")) reg bp(GO:signaling)
p(COVID:ORF1ab, frag("5325_5925")) reg bp(GO:signaling)
p(UNIPROT:P0DTD2) reg bp(GO:signaling)
p(COVID:N) reg bp(GO:signaling)
p(COVID:ORF1ab, frag("4141_4253")) reg bp(GO:"nuclear transport")
p(COVID:ORF1ab, frag("6453_6798")) reg bp(GO:"nuclear transport")
p(COVID:ORF6) reg bp(GO:"nuclear transport")
p(COVID:ORF1ab, frag("1_180")) reg a(GO:cytoskeleton)
p(COVID:ORF1ab, frag("5325_5925")) reg a(GO:cytoskeleton)
p(COVID:ORF1ab, frag("2764_3263")) reg a(GO:mitochondrion)
p(COVID:ORF1ab, frag("3943_4140")) reg a(GO:mitochondrion)
p(COVID:ORF1ab, frag("4141_4253")) reg a(GO:"extracellular matrix")

SET Evidence = "For wild-type Nsp5, we identified one high-confidence interaction, the epigenetic regulator histone deacetylase 2 (HDAC2), and predicted a cleavage site between the HDAC domain and the nuclear localization sequence, suggesting that Nsp5 may inhibit HDAC2 transport into the nucleus (Extended Data Fig. 7), potentially impacting the published functions of HDAC2 in mediating inflammation and interferon response 38,39."

complex(p(COVID:ORF1ab, frag("3264_3569")),p(HGNC:HDAC2)) -| tloc(p(HGNC:HDAC2), fromLoc(GO:"cytoplasmic region"), toLoc(GO:nucleus))
tloc(p(HGNC:HDAC2), fromLoc(GO:"cytoplasmic region"), toLoc(GO:nucleus)) -> act(p(HGNC:HDAC2))
act(p(HGNC:HDAC2)) reg bp(GO:"inflammatory response")
act(p(HGNC:HDAC2)) reg bp(GO:"response to type I interferon")

SET Evidence = "We also identified an interaction of Nsp5 (C145A) with tRNA methyltransferase 1 (TRMT1), which is responsible for synthesis of the dimethylguanosine (m2,2G) base modification on both nuclear and mitochondrial tRNAs 40 ."
complex(p(COVID:ORF1ab, frag("3264_3569")),p(HGNC:TRMT1)) reg act(p(HGNC:TRMT1))

SET Evidence = "Interestingly, we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 (TBK1) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD)."

complex(p(COVID:ORF1ab, frag("5325_5925")),p(HGNC:TBK1)) reg bp(GO:"type I interferon signaling pathway")
complex(p(COVID:ORF1ab, frag("5325_5925")),p(HGNC:TBKBP1)) reg bp(GO:"type I interferon signaling pathway")

SET Evidence = "Further, Nsp13 interacts with multiple proteins of the TLE family, which are known to modulate NF-ÎºB inflammatory response 42â44."

complex(p(COVID:ORF1ab, frag("5325_5925")),p(HGNC:TLE1)) reg act(p(GFAM:"NF-kappa B complex subunits"))
complex(p(COVID:ORF1ab, frag("5325_5925")),p(HGNC:TLE3)) reg act(p(GFAM:"NF-kappa B complex subunits"))
complex(p(COVID:ORF1ab, frag("5325_5925")),p(HGNC:AES)) reg act(p(GFAM:"NF-kappa B complex subunits"))

SET Evidence = "RNF41/Nrdp1, an E3 ubiquitin ligase is targeted by Nsp15 protein which promotes activation of TBK1 and IRF3 and therefore increases type I interferon production 45."

complex(p(COVID:ORF1ab, frag("6453_6798")),p(HGNC:RNF41)) -> act(p(HGNC:TBK1))
complex(p(COVID:ORF1ab, frag("6453_6798")),p(HGNC:RNF41)) -> act(p(HGNC:IRF3))
act(p(HGNC:TBK1)) -> bp(GO:"type I interferon biosynthetic process")
act(p(HGNC:IRF3)) -> bp(GO:"type I interferon biosynthetic process")

SET Evidence = "Two other E3 ubiquitin ligases, TRIM59 and MIB1 regulate antiviral innate immune signaling and are usurped by Orf3a and Nsp9, respectively 46,47 ."

complex(p(COVID:ORF3a),p(HGNC:TRIM59)) reg bp(GO:"induction of host immune response by virus")
complex(p(COVID:ORF1ab, frag("4141_4253")),p(HGNC:MIB1)) reg bp(GO:"induction of host immune response by virus")

SET Evidence = "Orf10 may bind to the CUL2 ZYG11B complex and hijack it for ubiquitination and degradation of restriction factors."

complex(p(COVID:ORF10),p(HGNC:CUL2),p(HGNC:ZYG11B)) -> bp(GO:"protein ubiquitination")

SET Evidence = "Surprisingly, we find that the transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4 (Fig. 4d, Extended Data Fig. 9), potentially disrupting BRD-histone binding by mimicking histone structure."

complex(p(COVID:E),p(HGNC:BRD2)) -| complex(p(HGNC:BRD2),p(GFAM:Histones))
complex(p(COVID:E),p(HGNC:BRD4)) -| complex(p(HGNC:BRD4),p(GFAM:Histones))

SET Evidence = "Among them, the well-known chemical probe, Bafilomycin A1, is a potent inhibitor of the V1-ATPase, subunits of which interact with Nsp6 and M."

a(CHEBI:"bafilomycin A1") -| complex(p(GFAM:"V-type ATPases"),p(COVID:ORF1ab, frag("3570_3859")))
a(CHEBI:"bafilomycin A1") -| complex(p(GFAM:"V-type ATPases"),p(COVID:M))

SET Evidence = "As a final example, we were intrigued to observe that the SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor, which is thought to regulate ER stress response 71 ."

complex(p(COVID:ORF1ab, frag("3570_3859")),p(HGNC:SIGMAR1)) reg bp(GO:"response to endoplasmic reticulum stress")

SET Evidence = "The human purine biosynthesis enzyme Inosine-5â²-monophosphate dehydrogenase (IMPDH2) interacts with the viral protein nsp14. Several chemically diverse compounds inhibit IMPDH2, including the clinically approved mycophenolic acid (20 nM), the approved antiviral drug ribavirin (200 nM), and the investigational new drug Merimepodib (10 nM) (Table 1a)."

act(p(HGNC:IMPDH2)) -> bp(GO:"purine nucleotide biosynthetic process")
complex(p(COVID:ORF1ab, frag("5926_6452")),p(HGNC:IMPDH2)) reg bp(GO:"purine nucleotide biosynthetic process")
a(CHEBI:"mycophenolic acid") -| act(p(HGNC:IMPDH2))
a(CHEBI:ribavirin) -| act(p(HGNC:IMPDH2))
a(PUBCHEM:153241) -| act(p(HGNC:IMPDH2))
UNSET Custom_Disease
UNSET Species

##################################################################################

# SET DOCUMENT Authors = "Yojana Gadiya"

SET Evidence = "The 5â Orf1a / Orf1ab encodes polyproteins, which are auto-proteolytically processed into 16 non-structural proteins (Nsp1-16) which form the replicase / transcriptase complex (RTC)."
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(FIXME:nsp1)
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(REFSEQ:"YP_009725298.1")
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(REFSEQ:"YP_009725299.1")
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(REFSEQ:"YP_009725300.1")
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(FIXME:nsp5)
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(UNIPROT:P0DTC6)
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(REFSEQ:"YP_009725303.1")
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(UNIPROT:P0DTC8)
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(REFSEQ:"YP_009725305.1")
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(REFSEQ:"YP_009725306.1")
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(REFSEQ:"YP_009725312.1")
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(FIXME:nsp12)
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(FIXME:nsp13)
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(FIXME:nsp14)
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(FIXME:nsp15)
p(REFSEQ:"YP_009724389.1",pmod(GOBP:proteolysis)) -> p(FIXME:nsp16)

SET Evidence = "The RTC consists of multiple enzymes, including the papain-like protease (Nsp3), the main protease (Nsp5), the Nsp7-Nsp8 primase complex, the primary RNA-dependent RNA polymerase (Nsp12), a helicase/triphosphatase (Nsp13), an exoribonuclease (Nsp14), an endonuclease (Nsp15), and N7- and 2âO-methyltransferases (Nsp10/Nsp16)[1,16,17]."
#RTC - replicase / transcriptase complex, 3.6.1.25 - triphosphatase, 2.1.1.57 - 2âO-methyltransferases, 2.1.1.56 - N7-methyltransferases
complex(GO:"viral replication complex") hasMembers list(p(REFSEQ:"YP_009725299.1"),p(FIXME:nsp5),p(REFSEQ:"YP_009725303.1"),p(UNIPROT:P0DTC8),p(FIXME:nsp12),p(FIXME:nsp13),p(FIXME:nsp14),p(FIXME:nsp15),p(REFSEQ:"YP_009725306.1"),p(FIXME:nsp16))
p(REFSEQ:"YP_009725299.1") -- p(MESH:Papain)
p(FIXME:nsp5) -- p(MESH:"Peptide Hydrolases")
composite(p(REFSEQ:"YP_009725303.1"),p(UNIPROT:P0DTC8)) -- p(MESH:"DNA Primase")
p(FIXME:nsp12) -- p(MESH:"RNA Replicase")
p(FIXME:nsp13) -- p(ECCODE:"3.6.1.25")
p(FIXME:nsp14) -- p(MESH:Exoribonucleases)
p(FIXME:nsp15) -- p(MESH:Endonucleases)
p(REFSEQ:"YP_009725306.1") -- p(ECCODE:"2.1.1.56")
p(FIXME:nsp16) -- p(ECCODE:"2.1.1.57")

SET Evidence = "For each of the viral proteins, we performed Gene Ontology enrichment analysis (Fig. 2b, Extended Data Fig. 2), identifying the major cell biological processes of the interacting proteins, including lipoprotein metabolism (S), nuclear transport (Nsp7), and biogenesis of ribonucleoprotein (Nsp8)."
#figure 2b
SET Experiment = "GO enrichment analysis"
p(REFSEQ:"YP_009725305.1") -- bp(GOBP:"posttranscriptional regulation of gene expression")
p(REFSEQ:"YP_009725305.1") -- bp(GOBP:"ribonucleoprotein complex biogenesis")
p(REFSEQ:"YP_009725305.1") reg a(CHEBI:"reactive oxygen species")
p(REFSEQ:"YP_009725305.1") -- bp(GOBP:"microtubule-based process")
p(REFSEQ:"YP_009725305.1") -- bp(GOBP:"gene silencing")
p(REFSEQ:"YP_009725305.1") -- bp(GOBP:"cellular component disassembly")
p(REFSEQ:"YP_009725305.1") -- bp(GOBP:"nuclear transport")
p(NCBIGENE:43740572) -- a(GO:"organelle inner membrane")
p(NCBIGENE:43740572) -- bp(GOBP:"gene silencing")
p(NCBIGENE:43740572) -- bp(GOBP:"cellular component disassembly")
p(NCBIGENE:43740572) -- bp(GOBP:"nuclear transport")
p(UNIPROT:P0DTC8) -- bp(GOBP:"ribonucleoprotein complex biogenesis")
p(UNIPROT:P0DTC8) -- bp(GOBP:"posttranscriptional regulation of gene expression")
p(UNIPROT:P0DTC8) -- bp(GOBP:"ribonucleoprotein complex biogenesis")
p(UNIPROT:P0DTC8) -- a(GO:"mitochondrial matrix")
p(UNIPROT:P0DTC8) reg a(CHEBI:"reactive oxygen species")
p(UNIPROT:P0DTC8) -- a(GO:"organelle inner membrane")
p(UNIPROT:P0DTC8) -- bp(GOBP:"cellular component disassembly")
p(NCBIGENE:"43740575") -- bp(GOBP:"posttranscriptional regulation of gene expression")
p(NCBIGENE:"43740575") -- bp(GOBP:"ribonucleoprotein complex biogenesis")
p(NCBIGENE:"43740575") -- bp(GOBP:"gene silencing")
p(NCBIGENE:"43740575") -- bp(GOBP:"nuclear transport")
p(REFSEQ:"YP_009725306.1") -- a(GO:"mitochondrial matrix")
p(REFSEQ:"YP_009725306.1") -- a(GO:"coated membrane")
p(REFSEQ:"YP_009725306.1") -- a(GO:"organelle envelope lumen")
p(REFSEQ:"YP_009725306.1") -- bp(GOBP:"microtubule-based process")
p(FIXME:nsp13) -- complex(GO:"HOPS complex")
p(FIXME:nsp13) -- bp(GOBP:"glycoprotein metabolic process")
p(FIXME:nsp13) -- bp(GOBP:"lipoprotein metabolic process")
p(FIXME:nsp13) -- bp(GOBP:"microtubule-based process")
p(FIXME:nsp14) -- a(GO:"mitochondrial matrix")
p(FIXME:nsp14) -- bp(GOBP:"glycoprotein metabolic process")
p(FIXME:nsp14) reg a(CHEBI:"reactive oxygen species")
p(FIXME:nsp14) -- a(GO:"organelle envelope lumen")
p(FIXME:nsp14) -- a(GO:"organelle inner membrane")
p(FIXME:nsp14) -- bp(GOBP:"gene silencing")
p(REFSEQ:"YP_009725300.1") -- a(GO:"organelle envelope lumen")
p(REFSEQ:"YP_009725300.1") -- a(GO:"organelle inner membrane")
p(REFSEQ:"YP_009725300.1") -- bp(GOBP:"gene silencing")
p(REFSEQ:"YP_009725300.1") -- bp(GOBP:"cellular component disassembly")
p(REFSEQ:"YP_009725300.1") -- bp(GOBP:"nuclear transport")
p(UNIPROT:P0DTC5) -- bp(GOBP:"posttranscriptional regulation of gene expression")
p(UNIPROT:P0DTC5) -- bp(GO:"secondary active transmembrane transporter activity")
p(UNIPROT:P0DTC5) -- a(GO:"mitochondrial matrix")
p(UNIPROT:P0DTC5) -- a(GO:"organelle inner membrane")
p(UNIPROT:P0DTC5) -- bp(GOBP:"microtubule-based process")
p(FIXME:nsp5,var("Cys145Ala")) -- bp(GOBP:"cell death in response to oxidative stress")
p(FIXME:nsp5,var("Cys145Ala")) -- a(GO:"mitochondrial matrix")
p(FIXME:nsp5,var("Cys145Ala")) -- bp(GOBP:"cellular component disassembly")
p(NCBIGENE:"43740577") -- complex(GO:"cytoplasmic ubiquitin ligase complex")
p(NCBIGENE:"43740577") -- bp(GOBP:"cell cycle G1/S phase transition")
p(NCBIGENE:"43740577") -- bp(GOBP:"glycoprotein metabolic process")
p(NCBIGENE:"43740577") -- bp(GOBP:"gene silencing")
p(UNIPROT:A0A663DJA2) -- complex(GO:"cytoplasmic ubiquitin ligase complex")
p(UNIPROT:A0A663DJA2) -- bp(GOBP:"cell cycle G1/S phase transition")
p(UNIPROT:A0A663DJA2) -- bp(GOBP:"lipoprotein metabolic process")
p(UNIPROT:A0A663DJA2) -- a(GO:"organelle inner membrane")
p(UNIPROT:A0A663DJA2) -- a(GO:"organelle envelope lumen")
p(FIXME:orf9b) -- bp(GOBP:"ribonucleoprotein complex biogenesis")
p(FIXME:orf9b) -- bp(GO:"tau-protein kinase activity")
p(FIXME:orf9b) -- a(GO:"coated membrane")
p(FIXME:orf9b) -- a(GO:"organelle inner membrane")
p(FIXME:orf9b) -- bp(GOBP:"cellular component disassembly")
p(FIXME:orf9c) -- bp(GO:"secondary active transmembrane transporter activity")
p(FIXME:orf9c) -- bp(GOBP:"glycoprotein metabolic process")
p(FIXME:orf9c) -- bp(GOBP:"lipoprotein metabolic process")
p(FIXME:orf9c) reg a(CHEBI:"reactive oxygen species")
p(FIXME:orf9c) -- a(GO:"organelle inner membrane")
p(FIXME:orf9c) -- bp(GOBP:"cellular component disassembly")
p(UNIPROT:P0DTC6) -- bp(GO:"secondary active transmembrane transporter activity")
p(UNIPROT:P0DTC6) -- a(GO:"organelle inner membrane")
p(NCBIGENE:"43740568") -- bp(GOBP:"lipoprotein metabolic process")
p(REFSEQ:"YP_009725303.1") -- bp(GOBP:"glycoprotein metabolic process")
p(REFSEQ:"YP_009725303.1") -- bp(GOBP:"lipoprotein metabolic process")
p(REFSEQ:"YP_009725303.1") -- a(GO:"organelle inner membrane")
p(REFSEQ:"YP_009725303.1") -- bp(GOBP:"microtubule-based process")
p(REFSEQ:"YP_009725303.1") -- bp(GOBP:"nuclear transport")
p(NCBIGENE:"43740570") -- bp(GO:"lysine-acetylated histone binding")
p(NCBIGENE:"43740570") -- a(GO:"coated membrane")
p(NCBIGENE:"43740570") -- bp(GOBP:"cell cycle G1/S phase transition")
p(NCBIGENE:"43740570") -- bp(GOBP:"microtubule-based process")
p(FIXME:nsp1) -- bp(GOBP:"cell cycle G1/S phase transition")
p(FIXME:nsp1) -- bp(GOBP:"nuclear transport")

SET Evidence = "Our study highlighted interactions between SARS-CoV-2 proteins and human proteins with a range of functions including DNA replication (Nsp1), epigenetic and gene expression regulators (Nsp5, Nsp8, Nsp13, E), vesicle trafficking (Nsp6, Nsp7, Nsp10, Nsp13, Nsp15, Orf3a, E, M, Orf8), lipid modification (Spike), RNA processing and regulation (Nsp8, N), ubiquitin ligases (Orf10), signaling (Nsp8, Nsp13, N, Orf9b), nuclear transport machinery (Nsp9, Nsp15, Orf6), cytoskeleton (Nsp1, Nsp13), mitochondria (Nsp4, Nsp8, Orf9c), and extracellular matrix (Nsp9) (Fig. 3)."
p(FIXME:nsp1) -- bp(GOBP:"DNA replication")
p(FIXME:nsp5) -- bp(GOBP:"regulation of gene expression, epigenetic")
p(UNIPROT:P0DTC8) -- bp(GOBP:"regulation of gene expression, epigenetic")
p(FIXME:nsp13) -- bp(GOBP:"regulation of gene expression, epigenetic")
p(NCBIGENE:"43740570") -- bp(GOBP:"regulation of gene expression, epigenetic")
p(UNIPROT:P0DTC6) -- bp(GOBP:"vesicle-mediated transport")
p(REFSEQ:"YP_009725303.1") -- bp(GOBP:"vesicle-mediated transport")
p(REFSEQ:"YP_009725306.1") -- bp(GOBP:"vesicle-mediated transport")
p(FIXME:nsp13) -- bp(GOBP:"vesicle-mediated transport")
p(FIXME:nsp15) -- bp(GOBP:"vesicle-mediated transport")
p(UNIPROT:P0DTC3) -- bp(GOBP:"vesicle-mediated transport")
p(NCBIGENE:"43740570") -- bp(GOBP:"vesicle-mediated transport")
p(UNIPROT:P0DTC5) -- bp(GOBP:"vesicle-mediated transport")
p(NCBIGENE:"43740577") -- bp(GOBP:"vesicle-mediated transport")
p(NCBIGENE:"43740568") -- bp(GOBP:"lipid modification")
p(UNIPROT:P0DTC8) -- bp(GOBP:"RNA processing")
p(NCBIGENE:"43740575") -- bp(GOBP:"RNA processing")
p(UNIPROT:A0A663DJA2) -- bp(GOBP:"modulation by virus of host ubiquitin-protein ligase activity")
p(UNIPROT:P0DTC8) -- bp(GOBP:signaling)
p(FIXME:nsp13) -- bp(GOBP:signaling)
p(NCBIGENE:"43740575") -- bp(GOBP:signaling)
p(FIXME:orf9b) -- bp(GOBP:signaling)
p(REFSEQ:"YP_009725305.1") -- bp(GOBP:"nuclear transport")
p(FIXME:nsp15) -- bp(GOBP:"nuclear transport")
p(NCBIGENE:43740572) -- bp(GOBP:"nuclear transport")
p(FIXME:nsp1) -- a(GO:cytoskeleton)
p(FIXME:nsp13) -- a(GO:cytoskeleton)
p(REFSEQ:"YP_009725300.1") -- a(GO:mitochondrion)
p(UNIPROT:P0DTC8) -- a(GO:mitochondrion)
p(FIXME:orf9c) -- a(GO:mitochondrion)
p(REFSEQ:"YP_009725305.1") -- a(GO:"extracellular matrix")
UNSET Experiment

SET Evidence = "Interestingly, the Spike protein (S) interacts with the GOLGA7-ZDHHC5 acyl-transferase complex, which likely mediates palmitoylation on its cytosolic tail (see also Appendix) [35]. Palmitoylation has been reported to facilitate membrane fusion by SARS-CoV Spike and suggests a potential target for therapeutic inhibition [36]."
composite(p(NCBIGENE:"43740568"),complex(p(HGNC:GOLGA7),p(HGNC:ZDHHC5))) pos bp(GOBP:"protein palmitoylation")
bp(GOBP:"protein palmitoylation") pos bp(GOBP:"fusion of virus membrane with host outer membrane")

SET Evidence = "Interestingly, ZDHHC5 also has a published role in allowing anthrax toxin to enter cells, suggesting that inhibition of this enzyme could have broad utility [37]."
SET MeSHDisease = "Anthrax"
p(HGNC:ZDHHC5) pos tloc(a(MESH:"Toxins, Biological"),fromLoc(GOCC:"extracellular region"),toLoc(GOCC:intracellular))
UNSET MeSHDisease

SET Evidence = "Host interactions of Nsp8 (signal recognition particle), Orf8 (endoplasmic reticulum quality control), M (ER structural morphology proteins), Nsp13 (golgins) may facilitate the dramatic reconfiguration of ER/Golgi trafficking during coronavirus infection, and interactions in peripheral compartments by Nsp6 and M (vacuolar ATPase), Nsp7 (Rabs), Nsp10 (AP2), E (AP3), and Orf3a (HOPS) may also modify endomembrane compartments to favor coronavirus replication."
p(UNIPROT:P0DTC8) -- complex(GO:"signal recognition particle")
p(NCBIGENE:"43740577") -- a(GO:"endoplasmic reticulum quality control compartment")
SET MeSHAnatomy = "Endoplasmic Reticulum"
p(UNIPROT:P0DTC5) -- path(MESH:"Molecular Structure")
UNSET MeSHAnatomy
SET MeSHDisease = "Coronavirus Infections"
p(UNIPROT:P0DTC8) reg bp(GOBP:"regulation of ER to Golgi vesicle-mediated transport")
p(NCBIGENE:"43740577") reg bp(GOBP:"regulation of ER to Golgi vesicle-mediated transport")
p(UNIPROT:P0DTC5) reg bp(GOBP:"regulation of ER to Golgi vesicle-mediated transport")
p(FIXME:nsp13) reg bp(GOBP:"regulation of ER to Golgi vesicle-mediated transport")
composite(p(UNIPROT:P0DTC6,loc(GOCC:"endomembrane system")),complex(GO:"vacuolar proton-transporting V-type ATPase complex",loc(GOCC:"endomembrane system"))) reg bp(FIXME:"SARS-CoV-2 replication")
composite(p(UNIPROT:P0DTC5,loc(GOCC:"endomembrane system")),complex(GO:"vacuolar proton-transporting V-type ATPase complex",loc(GOCC:"endomembrane system"))) reg bp(FIXME:"SARS-CoV-2 replication")
composite(p(REFSEQ:"YP_009725303.1",loc(GOCC:"endomembrane system")),p(MESH:"rab GTP-Binding Proteins",loc(GOCC:"endomembrane system"))) reg bp(FIXME:"SARS-CoV-2 replication")
composite(p(REFSEQ:"YP_009725306.1",loc(GOCC:"endomembrane system")),p(GFAM:"Adaptor related protein complex 2",loc(GOCC:"endomembrane system"))) reg bp(FIXME:"SARS-CoV-2 replication")
composite(p(NCBIGENE:"43740570",loc(GOCC:"endomembrane system")),p(GFAM:"Adaptor related protein complex 3",loc(GOCC:"endomembrane system"))) reg bp(FIXME:"SARS-CoV-2 replication")
composite(p(UNIPROT:P0DTC3,loc(GOCC:"endomembrane system")),complex(GO:"HOPS complex",loc(GOCC:"endomembrane system"))) reg bp(FIXME:"SARS-CoV-2 replication")
UNSET MeSHDisease

SET Evidence = "For wild-type Nsp5, we identified one high-confidence interaction, the epigenetic regulator histone deacetylase 2 (HDAC2), and predicted a cleavage site between the HDAC domain and the nuclear localization sequence, suggesting that Nsp5 may inhibit HDAC2 transport into the nucleus (Extended Data Fig. 7), potentially impacting the published functions of HDAC2 in mediating inflammation and interferon response [38,39]."
p(FIXME:nsp5) -| p(HGNC:HDAC2,loc(GOCC:nucleus))
SET MeSHAnatomy = "Cell Nucleus"
act(p(HGNC:HDAC2)) pos bp(GOBP:"inflammatory response")
p(FIXME:nsp5) -| bp(GOBP:"inflammatory response")
act(p(HGNC:HDAC2)) pos act(p(MESH:Interferons))
p(FIXME:nsp5) -| act(p(MESH:Interferons))
UNSET MeSHAnatomy

SET Evidence = "We also identified an interaction of Nsp5 (C145A) with tRNA methyltransferase 1 (TRMT1), which is responsible for synthesis of the dimethylguanosine (m2,2G) base modification on both nuclear and mitochondrial tRNAs [40]. We predict TRMT1 is also cleaved by Nsp5, removing its zinc finger and nuclear localization signal and likely resulting in an exclusively mitochondrial localization (Extended Data Fig. 7)."
#135501639 - N2,N2-dimethylguanosine
p(HGNC:TRMT1) -> a(PUBCHEM:135501639)
a(PUBCHEM:135501639) pos bp(GOBP:"mitochondrial tRNA modification")
SET MeSHAnatomy = "Cell Nucleus"
a(PUBCHEM:135501639) pos bp(GOBP:"tRNA modification")
UNSET MeSHAnatomy
composite(p(FIXME:nsp5,var("Cys145Ala")),p(HGNC:TRMT1)) reg act(p(HGNC:TRMT1))

SET Evidence = "Interestingly, we found that Nsp13 interacts with two key players of IFN signaling pathway including TANK-binding kinase 1 (TBK1) and TANK-binding kinase 1-binding protein 1 (TBKBP1/SINTBAD).SINTBAD acts as a critical adaptor protein between TBK1 and IKKi and therefore mediates induction of IRF-dependent transcription [41]. "
p(HGNC:TBK1) -- bp(GOBP:"type I interferon signaling pathway")
p(HGNC:TBKBP1) -- bp(GOBP:"type I interferon signaling pathway")
composite(p(FIXME:nsp13),p(HGNC:TBK1)) reg bp(GOBP:"type I interferon signaling pathway")
composite(p(FIXME:nsp13),p(HGNC:TBKBP1)) reg bp(GOBP:"type I interferon signaling pathway")
p(HGNC:TBK1) ->  composite(p(HGNC:TBK1),p(HGNC:TBKBP1))
composite(p(HGNC:TBK1),p(HGNC:TBKBP1)) -> complex(p(HGNC:TBK1),p(HGNC:TBKBP1),complex(GO:"IkappaB kinase complex"))
complex(p(HGNC:TBK1),p(HGNC:TBKBP1),complex(GO:"IkappaB kinase complex")) -> act(p(HGNC:IRF1))
act(p(HGNC:IRF1)) -> bp(MESHPP:"Transcription, Genetic")

SET Evidence = "RNF41/Nrdp1, an E3 ubiquitin ligase is targeted by Nsp15 protein which promotes activation of TBK1 and IRF3 and therefore increases type I interferon production [45]."
p(FIXME:nsp15) -> p(HGNC:RNF41)
p(HGNC:RNF41) -> act(p(HGNC:TBK1))
p(HGNC:RNF41) -> act(p(HGNC:IRF3))
act(p(HGNC:TBK1)) -> bp(GOBP:"type I interferon secretion")
act(p(HGNC:IRF3)) -> bp(GOBP:"type I interferon secretion")
p(HGNC:RNF41) -> bp(GOBP:"type I interferon secretion")

SET Evidence = "Two other E3 ubiquitin ligases, TRIM59 and MIB1 regulate antiviral innate immune signaling and are usurped by Orf3a and Nsp9, respectively [46,47]."
p(UNIPROT:P0DTC3) -> deg(p(HGNC:TRIM59))
p(REFSEQ:"YP_009725305.1") -> deg(p(HGNC:MIB1))
p(HGNC:TRIM59) reg bp(GOBP:"active induction of innate immune response in host by virus")
p(HGNC:MIB1) reg bp(GOBP:"active induction of innate immune response in host by virus")

SET Evidence = "Orf9c protein was found to interact with multiple proteins that modulate IkB kinase and NF-kB signaling pathway including NLRX1, F2RL1, NDFIP2 [48â50]."
composite(p(FIXME:orf9c),p(HGNC:NLRX1),p(HGNC:F2RL1),p(HGNC:NDFIP2)) reg bp(GOBP:"I-kappaB kinase/NF-kappaB signaling")

SET Evidence = "We also found that Orf9b interacts with a mitochondrial import receptor, Tom70, which acts as an essential adaptor linking MAVS to TBK1/IRF3, resulting in the activation of IRF-3 [51]."
composite(p(FIXME:orf9b),p(HGNC:TOMM70)) -> act(p(HGNC:IRF3))

SET Evidence = "N targets stress granule protein G3BP1, an essential antiviral protein which is known to induce innate immune response through multiple mechanisms [52â54]."
composite(p(NCBIGENE:"43740575"),p(HGNC:G3BP1)) reg bp(GOBP:"active induction of innate immune response in host by virus")
p(HGNC:G3BP1) pos bp(GOBP:"active induction of innate immune response in host by virus")

SET Evidence = "The SARS-CoV-2 nucleocapsid (N) interactome includes many host mRNA binding proteins, including the SG related factors G3BP1/2, the mTOR translational repressors LARP1, and the protein kinases CK2 (Fig. 4a)."
#2.7.11.1 - CK2
composite(p(NCBIGENE:"43740575"),p(HGNC:G3BP2)) reg act(p(HGNC:G3BP2))
composite(p(NCBIGENE:"43740575"),p(HGNC:LARP1)) reg act(p(HGNC:LARP1))
p(HGNC:LARP1) -| act(p(HGNC:MTOR),ma(GOBP:translation))
composite(p(NCBIGENE:"43740575"),p(ECCODE:"2.7.11.1")) reg act(p(ECCODE:"2.7.11.1"))

SET Evidence = "SGs are induced by protein kinase R (PKR)-mediated phosphorylation of eIF2Î± upon viral dsRNA recognition [57]. Promoting G3BP aggregation via the eIF4A inhibitor Zotatafin [58,59] or reducing SG disassembly by Silmitasertib inhibition of CK2 [60] warrant investigation for treatment of SARS-CoV-2. The mTOR inhibitor rapamycin disrupts the binding of LARP1 to mTORC1 [61] and has been shown to reduce MERS infection by â¼60% in vitro [62], another drug that could be tested for repurposing."
#SG - stress granules
#EIF2AK2 - PKR, 24748573 - Silmitasertib, 2.7.11.1 - CK2, sirolimus - rapamycin
bp(GOBP:"detection of virus") -> act(p(HGNC:EIF2AK2))
act(p(HGNC:EIF2AK2)) -> p(HGNC:EIF2A,pmod(Ph))
p(HGNC:EIF2A,pmod(Ph)) -> bp(GOBP:"stress granule assembly")
p(HGNC:EIF4A1) -| p(HGNC:G3BP1,pmod(CONSO:"protein aggregates"))
p(HGNC:EIF4A1) pos path(DO:"COVID-19")
a(PUBCHEM:24748573) -| p(ECCODE:"2.7.11.1")
a(PUBCHEM:24748573) -| bp(GOBP:"stress granule disassembly")
a(PUBCHEM:24748573) -| path(DO:"COVID-19")
a(CHEBI:sirolimus) -| p(HGNC:MTOR)
a(CHEBI:sirolimus) -| complex(p(HGNC:LARP1),p(GFAM:"MTOR complex 1"))
a(CHEBI:sirolimus) -| path(MESH:"Coronavirus Infections")

SET Evidence = "Orf6 of SARS-CoV has been shown to play a role in antagonizing host interferon signaling [63]; we identified a novel, high-confidence interaction between SARS-CoV-2 Orf6 and NUP98-RAE1, an interferon-inducible mRNA nuclear export complex [64] that is hijacked or degraded by multiple viruses, including VSV, Influenza-A, KSHV, and Polio, and is a restriction factor for Influenza-A infection [58,60,62,65]. These binding features are also present in a conserved motif in the C-terminal region of SARS-CoV-2 Orf6 (Fig. 4b, Extended Data Fig. 8), providing a structural hypothesis for the observed SARS-CoV-2âNUP98-RAE1 interaction."
#NUP98-RAE1 complex used for mrna export
p(NCBIGENE:43740572) -| bp(GOBP:"type I interferon signaling pathway")
composite(complex(p(HGNC:NUP98),p(HGNC:RAE1)),p(NCBIGENE:43740572,frag("?_*"))) reg bp(GOBP:"mRNA export from nucleus")

SET Evidence = "Orf10 may bind to the CUL2-ZYG11B complex and hijack it for ubiquitination and degradation of restriction factors. The ubiquitin transfer to a substrate requires neddylation of CUL2 via NEDD8-activating enzyme (NAE), a druggable target that can be inhibited by the small molecule Pevonedistat [68] (Fig. 4c)."
#Pevonedistat - DB11759
composite(complex(p(HGNC:CUL2),p(HGNC:ZYG11B)),p(UNIPROT:A0A663DJA2)) reg bp(GOBP:"protein ubiquitination")
act(p(HGNC:NAE1)) -> act(p(HGNC:CUL2))
act(p(HGNC:CUL2)) -> p(MESH:Proteins,pmod(Ub))
a(DRUGBANK:DB11759) -| act(p(HGNC:NAE1))

SET Evidence = "Surprisingly, we find that the transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4 (Fig. 4d, Extended Data Fig. 9), potentially disrupting BRD-histone binding by mimicking histone structure.BRD2 is a member of the bromodomain and extra-terminal (BET) domain family whose members bind acetylated histones to regulate gene transcription [69]."
composite(p(NCBIGENE:"43740570"),p(HGNC:BRD2)) -| complex(p(HGNC:BRD2),p(MESH:Histones))
composite(p(NCBIGENE:"43740570"),p(HGNC:BRD4)) -| complex(p(HGNC:BRD4),p(MESH:Histones))
complex(p(HGNC:BRD2),p(MESH:Histones,pmod(Ac))) reg bp(GOBP:"gene expression")

SET Evidence = "Chemoinformatics searches yielded 15 approved drugs, four investigational new drugs (clinical), and 18 pre-clinical candidates (Table 1a), while specialist knowledge revealed 12 approved drugs, 10 investigational new drugs (clinical), and 10 preclinical candidates (Table 1b)."
#table 1a
#DB12000 - RVX-208, 24748573 - Silmitasertib, 6918328 - Apicidin, 44247568 - E-52862, 10474335 - pb28, DB07995 - h-89, DB04862 - Merimepodib, DB00811 - ribavarin, 135564632 - XL413, - cct 365623, 9589606 - ac-55541, - az8838, 49843508 - gb110
SET Experiment = "Literature derived"
a(CHEBI:JQ1) -| p(HGNC:BRD2)
a(CHEBI:JQ1) -| p(HGNC:BRD4)
a(CHEBI:JQ1) -- p(NCBIGENE:"43740570")
a(DRUGBANK:DB12000) -| p(HGNC:BRD2)
a(DRUGBANK:DB12000) -| p(HGNC:BRD4)
a(DRUGBANK:DB12000) -- p(NCBIGENE:"43740570")
a(PUBCHEM:24748573) -- p(NCBIGENE:"43740575")
a(PUBCHEM:6918328) -| p(HGNC:HDAC2)
a(PUBCHEM:6918328) -- p(FIXME:nsp5)
a(CHEBI:"valproic acid") -| p(HGNC:HDAC2)
a(CHEBI:"valproic acid") -- p(FIXME:nsp5)
a(CHEBI:"bafilomycin A1") -| p(HGNC:ATP6AP1)
a(CHEBI:"bafilomycin A1") -- p(UNIPROT:P0DTC6)
a(CHEBI:"bafilomycin A1") -| p(HGNC:ATP6V1A)
a(CHEBI:"bafilomycin A1") -- p(UNIPROT:P0DTC5)
a(PUBCHEM:44247568) -| p(HGNC:SIGMAR1)
a(PUBCHEM:44247568) -- p(UNIPROT:P0DTC6)
a(PUBCHEM:10474335) reg p(HGNC:SIGMAR1)
a(PUBCHEM:10474335) -- p(UNIPROT:P0DTC6)
a(PUBCHEM:10474335) reg p(HGNC:TMEM97)
a(PUBCHEM:10474335) -- p(FIXME:orf9c)
a(CHEBI:haloperidol) reg p(HGNC:SIGMAR1)
a(CHEBI:haloperidol) -- p(UNIPROT:P0DTC6)
a(CHEBI:haloperidol) reg p(HGNC:TMEM97)
a(CHEBI:haloperidol) -- p(FIXME:orf9c)
a(CHEBI:haloperidol) neg path(DO:"central nervous system disease")
a(CHEBI:entacapone) -| p(HGNC:COMT)
a(CHEBI:entacapone) -- p(REFSEQ:"YP_009725303.1")
a(CHEBI:entacapone) neg path(EFO:"Parkinson's disease")
a(CHEBI:indometacin) -| p(HGNC:PTGES2)
a(CHEBI:indometacin) -- p(REFSEQ:"YP_009725303.1")
a(CHEBI:indometacin) neg bp(GOBP:"inflammatory response")
a(CHEBI:indometacin) neg path(MESH:Pain)
a(DRUGBANK:DB00331) -| p(GFAM:"NADH:ubiquinone oxidoreductase supernumerary subunits")
a(DRUGBANK:DB00331) -- p(REFSEQ:"YP_009725303.1")
a(DRUGBANK:DB00331) -- p(FIXME:orf9c)
a(CHEBI:ponatinib) -| p(HGNC:RIPK1)
a(CHEBI:ponatinib) -- p(FIXME:nsp12)
a(CHEBI:ponatinib) neg path(DO:cancer)
a(DRUGBANK:DB07995) -| p(HGNC:PRKACA)
a(DRUGBANK:DB07995) -- p(FIXME:nsp13)
a(DRUGBANK:DB04862) -| p(HGNC:IMPDH2)
a(DRUGBANK:DB04862) -- p(FIXME:nsp14)
a(CHEBI:migalastat) -| p(HGNC:GLA)
a(CHEBI:migalastat) -- p(FIXME:nsp14)
a(CHEBI:migalastat) neg path(DO:"Fabry disease")
a(CHEBI:migalastat) -| p(HGNC:GLA)
a(CHEBI:migalastat) -- p(FIXME:nsp14)
a(CHEBI:migalastat) neg path(DO:"Fabry disease")
a(CHEBI:"mycophenolic acid") -| p(HGNC:IMPDH2)
a(CHEBI:"mycophenolic acid") -- p(FIXME:nsp14)
a(CHEBI:"mycophenolic acid") neg path(MESH:"Graft Rejection")
a(DRUGBANK:DB00811) -| p(HGNC:IMPDH2)
a(DRUGBANK:DB00811) -- p(FIXME:nsp14)
a(DRUGBANK:DB00811) neg path(MESH:"Virus Diseases")
a(PUBCHEM:135564632) -| p(HGNC:CDC7)
a(PUBCHEM:135564632) -- p(NCBIGENE:"43740577")
a(PUBCHEM:139266765) -| p(HGNC:LOXL2)
a(PUBCHEM:139266765) -- p(NCBIGENE:"43740577")
a(CHEBI:midostaurin) -| p(HGNC:MARK1)
a(CHEBI:midostaurin) -| p(HGNC:MARK3)
a(CHEBI:midostaurin) -- p(FIXME:orf9b)
a(CHEBI:midostaurin) neg path(DO:cancer)
a(CHEBI:ruxolitinib) -| p(HGNC:MARK1)
a(CHEBI:ruxolitinib) -| p(HGNC:MARK3)
a(CHEBI:ruxolitinib) -- p(FIXME:orf9b)
a(CHEBI:ruxolitinib) neg path(DO:myelofibrosis)
a(PUBCHEM:9589606) -> p(HGNC:F2RL1)
a(PUBCHEM:9589606) -- p(FIXME:orf9c)
a(PUBCHEM:126961334) -> p(HGNC:F2RL1)
a(PUBCHEM:126961334) -- p(FIXME:orf9c)
a(CHEBI:daunorubicin) -- p(FIXME:orf9c)
a(CHEBI:daunorubicin) neg path(DO:cancer)
a(PUBCHEM:49843508) -> p(HGNC:F2RL1)
a(PUBCHEM:49843508) -- p(FIXME:orf9c)
a(CHEBI:"(S)-verapamil") -- p(FIXME:orf9c)
a(CHEBI:"(S)-verapamil") neg path(DO:hypertension)
UNSET Experiment
#table 1b
#abbv-744 - 132010322, dbet6 - 121427831, mz1 - 122201421, cpi-0610 - 57389999, sapanisertib - DB11836, rapamycin - sirolimus, zotatifin - 129138801, verdinexor - DB12207, Sanglifehrin A - DB03393, fk-506 - DB00864, DB11759 - Pevonedistat
SET Experiment = "Expert identified"
a(PUBCHEM:132010322) -| p(HGNC:BRD2)
a(PUBCHEM:132010322) -| p(HGNC:BRD4)
a(PUBCHEM:132010322) -- p(NCBIGENE:"43740570")
a(PUBCHEM:121427831) -> deg(p(HGNC:BRD2))
a(PUBCHEM:121427831) -> deg(p(HGNC:BRD4))
a(PUBCHEM:121427831) -- p(NCBIGENE:"43740570")
a(PUBCHEM:122201421) -> deg(p(HGNC:BRD2))
a(PUBCHEM:122201421) -> deg(p(HGNC:BRD4))
a(PUBCHEM:122201421) -- p(NCBIGENE:"43740570")
a(PUBCHEM:57389999) -| p(HGNC:BRD2)
a(PUBCHEM:57389999) -| p(HGNC:BRD4)
a(PUBCHEM:57389999) -- p(NCBIGENE:"43740570")
a(DRUGBANK:DB11836) -| p(HGNC:MTOR)
a(DRUGBANK:DB11836) -- p(NCBIGENE:"43740575")
a(CHEBI:sirolimus) -| p(HGNC:MTOR)
a(CHEBI:sirolimus) -| p(HGNC:FKBP15)
a(CHEBI:sirolimus) -| p(HGNC:FKBP7)
a(CHEBI:sirolimus) -| p(HGNC:FKBP10)
a(CHEBI:sirolimus) -- p(NCBIGENE:"43740575")
a(CHEBI:sirolimus) -- p(REFSEQ:"YP_009725298.1")
a(CHEBI:sirolimus) -- p(NCBIGENE:"43740577")
a(CHEBI:sirolimus) neg bp(MESH:"Graft Rejection")
a(PUBCHEM:129138801) -| p(HGNC:EIF4A1)
a(PUBCHEM:129138801) -- p(REFSEQ:"YP_009725298.1")
a(DRUGBANK:DB12207) -| p(HGNC:XPO1)
a(DRUGBANK:DB12207) -- p(REFSEQ:"YP_009725300.1")
a(DRUGBANK:DB12207) -- p(REFSEQ:"YP_009725305.1")
a(DRUGBANK:DB12207) -- p(NCBIGENE:43740572)
a(CHEBI:chloroquine) -- complex(a(CHEBI:chloroquine),p(HGNC:SIGMAR1))
a(CHEBI:chloroquine) -- p(UNIPROT:P0DTC6)
a(CHEBI:chloroquine) neg path(DO:malaria)
a(CHEBI:dabrafenib) -| p(HGNC:NEK9)
a(CHEBI:dabrafenib) -- p(REFSEQ:"YP_009725305.1")
a(CHEBI:dabrafenib) neg path(DO:cancer)
a(DRUGBANK:DB03393) reg p(HGNC:IMPDH2)
a(DRUGBANK:DB03393) -- p(FIXME:nsp14)
a(DRUGBANK:DB00864) -| p(HGNC:FKBP7)
a(DRUGBANK:DB00864) -| p(HGNC:FKBP10)
a(DRUGBANK:DB00864) -- p(NCBIGENE:"43740577")
a(DRUGBANK:DB00864) neg bp(MESH:"Graft Rejection")
a(DRUGBANK:DB11759) -| p(HGNC:NEDD8)
a(DRUGBANK:DB11759) -- p(UNIPROT:A0A663DJA2)
a(CHEBI:linezolid) -| complex(GO:"mitochondrial ribosome")
a(CHEBI:tigecycline) -| complex(GO:"mitochondrial ribosome")
a(CHEBI:chloramphenicol) -| complex(GO:"mitochondrial ribosome")
a(CHEBI:nafamostat) -| p(HGNC:PRSS1)
a(CHEBI:nafamostat) -- bp(GOBP:"viral entry into host cell")
a(CHEBI:camostat) -| p(HGNC:PRSS1)
a(CHEBI:camostat) -- bp(GOBP:"viral entry into host cell")
a(CHEBI:captopril) -| p(HGNC:ACE)
a(CHEBI:captopril) -- bp(GOBP:"viral entry into host cell")
a(CHEBI:lisinopril) -| p(HGNC:ACE)
a(CHEBI:lisinopril) -- bp(GOBP:"viral entry into host cell")

SET Evidence  = "Among them, the well-known chemical probe, Bafilomycin A1, is a potent inhibitor of the V1-ATPase, subunits of which interact with Nsp6 and M. Bafilomycinâs inhibition of this cotransporter acts to prevent the acidification of the lysosome, inhibiting autophagy and endosome trafficking pathways, which may impact the viral life-cycle."
a(CHEBI:"bafilomycin A1") -| complex(GO:"lysosomal proton-transporting V-type ATPase, V1 domain")
SET MeSHAnatomy = "Lysosomes"
a(CHEBI:"bafilomycin A1") -| bp(GOBP:"pH reduction")
UNSET MeSHAnatomy
a(CHEBI:"bafilomycin A1") -| bp(GOBP:autophagy)
a(CHEBI:"bafilomycin A1") -| bp(GOBP:"endosomal transport")

SET Evidence = "As a final example, we were intrigued to observe that the SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor, which is thought to regulate ER stress response [71]."
composite(p(UNIPROT:P0DTC6),p(HGNC:SIGMAR1)) reg bp(GOBP:"response to endoplasmic reticulum stress")
p(HGNC:SIGMAR1) reg bp(GOBP:"response to endoplasmic reticulum stress")

SET Evidence = "Intriguingly, the preclinical molecule Sanglifehrin A (Table 1b) is known to act as a molecular glue linking IMPDH with cyclophilin A (Fig. 5b)73, which itself is implicated in viral capsid packaging, even though it itself is not a human âpreyâ in the viral-human protein interactome."
#DB03393 - Sanglifehrin A
a(DRUGBANK:DB03393) -> complex(p(HGNC:IMPDH1),p(MESH:"Cyclophilin A"))
complex(p(HGNC:IMPDH1),p(MESH:"Cyclophilin A")) reg bp(GOBP:"viral capsid assembly")

